“Cellular And Humoral Immunogenicity Of Admva, A Clade C/b Mva-Based Hiv-1 Candidate Vaccine, In Healthy Volunteers”. In Aids Vaccine 2007 Conference. Aids Vaccine 2007 Conference. Seattle, WA. http://www.vaccineenterprise.org/conference_archive/2007/index.html.
. 2007. “A Phase 2 Study To Evaluate The Safety And Immunogenicity Of A Recombinant Adeno-Associated Virus Hiv Vaccine”. In Aids Vaccine 2007 Conference. Aids Vaccine 2007 Conference. Seattle, WA. http://www.vaccineenterprise.org/conference_archive/2007/index.html.
. 2007. “A Phase I Study To Evaluate The Safety And Immunogenicity Of A Recombinant Modified Vaccinia Ankara Virus (Tbc-M4) Multigenic Hiv Subtype C Vaccine”. In Aids Vaccine 2007 Conference. Aids Vaccine 2007 Conference. Seattle, WA. http://www.vaccineenterprise.org/conference_archive/2007/index.html.
. 2007. “Safety And Immunogenicity Of Vrc Multiclade Hiv-1 Adenoviral Vector Vaccine Alone Or With Vrc Multiclade Hiv-1 Dna Plasmid Vaccine In The African Adults”. In Aids Vaccine 2007 Conference. Aids Vaccine 2007 Conference. Seattle, WA. http://www.vaccineenterprise.org/conference_archive/2007/index.html.
. 2007. . 2010.
. 2010.
“A Phase 1 Study To Evaluate The Safety And Immunogenicity Of A Recombinant Hiv Type 1 Subtype C Adeno-Associated Virus Vaccine”. Aids Research And Human Retroviruses 24. Aids Research And Human Retroviruses: 873-880. http://www.ncbi.nlm.nih.gov/pubmed/18544020.
. 2008. “A Phase 2 Study To Evaluate The Safety And Immunogenicity Of A Recombinant Hiv Type 1 Vaccine Based On Adeno-Associated Virus”. Aids Res Hum Retroviruses 26. Aids Res Hum Retroviruses: 933-942. http://www.ncbi.nlm.nih.gov/pubmed/20666584.
. 2010.